Conference Coverage

VIDEO: Chondroitin tops celecoxib in reducing knee OA structural progression


 

AT THE ACR ANNUAL MEETING

References

SAN FRANCISCO – Patients with symptomatic knee osteoarthritis who received pharmaceutical-grade chondroitin sulfate for 2 years lost about 20% less cartilage volume than did patients treated with celecoxib, according to a randomized, double-blind trial.

Improvements were limited to the medial tibiofemoral compartment, but even such modest structural effects can significantly decrease rates of total knee replacement over time, said lead investigator Dr. Jean-Pierre Pelletier, who presented the findings at the annual meeting of the American College of Rheumatology.

The 194 participants in the study received chondroitin sulfate, 1,200 mg a day, or celecoxib, 200 mg daily. Joint effusion and pain and function improved markedly in both groups, and they had similar rates of adverse events, said Dr. Pelletier, who is a rheumatologist at Institut de recherche en rhumatologie de Montréal. He discussed the findings and plans for future research in an exclusive video interview.

Bioibérica sponsored the study and makes the chondroitin sulfate that participants received. Dr. Pelletier and his associates had no other disclosures.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Recall issued on U.S. Compounding sterile products
MDedge Family Medicine
Inflammatory features linked to erosive development in hand OA
MDedge Family Medicine
Study reveals patterns of concurrent MRI lesions in knee OA
MDedge Family Medicine
Serum HA cutoff predicts progression in knee OA
MDedge Family Medicine
Worsening of lesions on MRI predicts knee OA
MDedge Family Medicine
Benefits, risks of total knee replacement for OA illuminated in trial
MDedge Family Medicine
Louisiana goes two for one on controlled substance prescriptions
MDedge Family Medicine
FDA approves low-dose meloxicam medication for osteoarthritis
MDedge Family Medicine
ACR: No long-term benefit for knee OA steroid injections
MDedge Family Medicine
Jury still out on cannabinoid therapy for rheumatic diseases
MDedge Family Medicine